OBJECTIVE@#To explore the clinical characteristics,
treatment and
prognosis of
therapy-related
hematological neoplasms patients secondary to malignant solid
tumors.@*
METHODS@#The clinical features,
treatment and
prognosis of 36
hematological neoplasms patients secondary to malignant solid
tumors with
radiotherapy and
chemotherapy in the Second
Hospital of Shanxi Medical
University were retrospectively analyzed.@*RESULTS@#The 36
patients with
therapy-related
hematological neoplasms had a median age of 60 (47-81) years, 14 were
male and 22 were
female. Among them, 22 cases were
acute myeloid leukemia, 5 cases were
acute lymphoblastic leukemia, 4 cases were
multiple myeloma, 3 cases were
myelodysplastic syndrome, and 2 cases were non-hodgkin's lymphoma. The median latency of malignant
tumor to
hematological neoplasm was 42.5 (12-120) months. The median
survival time of
therapy-related
hematological neoplasms was 10.5 (1-83) months, and the 3-year overall
survival (OS) rate was 24.3%. The
therapy-related
acute myeloid leukemia patients had a very poor
prognosis, with a median
survival of 7 (1-83) months and a 3-year OS rate of 21.4%.@*CONCLUSION@#The
prognosis of
therapy-related
hematological neoplasms secondary to malignant solid
tumors with
radiotherapy and
chemotherapy is poor, and individualized
treatment should be implemented according to the clinical situation of
patients.